Abstract:Breast cancer (BC) is a highly metastatic multifactorial disease with various histological and molecular subtypes. Due to recent advancements, the mortality rate in BC has improved over the past five decades. Detection and treatment of many cancers are now possible due to the application of nanomedicine in clinical practice. Nanomedicine products such as Doxil® and Abraxane® have already been extensively used for BC adjuvant therapy with favorable clinical outcomes. However, these products were designed initially for generic anticancer purposes and not specifically for BC treatment. With a better understanding of the molecular biology of BC, several novel and promising nanotherapeutic strategies and devices have been developed in recent years. In this context, multi-functionalized nanostructures are becoming potential carriers for enhanced chemotherapy in BC patients. To design these nanostructures, a wide range of materials, such as proteins, lipids, polymers, and hybrid materials, can be used and tailored for specific purposes against BC. Selective targeting of BC cells results in the activation of programmed cell death in BC cells and can be considered a promising strategy for managing triple-negative BC. Currently, conventional BC screening methods such as mammography, digital breast tomosynthesis (DBT), ultrasonography, and magnetic resonance imaging (MRI) are either costly or expose the user to hazardous radiation that could harm them. Therefore, there is a need for such analytical techniques for detecting BC that are highly selective and sensitive, have a very low detection limit, are durable, biocompatible, and reproducible. In detecting BC biomarkers, nanostructures are used alone or in conjunction with numerous molecules. This review intends to highlight the recent advances in nanomedicine in BC treatment and diagnosis, emphasizing the targeting of BC cells that overexpress receptors of epidermal growth factors. Researchers may gain insight from these strategies to design and develop more tailored nanomedicine for BC to achieve further improvements in cancer specificity, antitumorigenic effects, anti-metastasis effects, and drug resistance reversal effects.

Impact of Nanomedicine in Women's Metastatic Breast Cancer (Small 41/2024)

Nano-Based Theranostic Platforms for Breast Cancer: A Review of Latest Advancements

(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy

Emerging nanomedicines for effective breast cancer immunotherapy

Nanomedicine in Treatment of Breast Cancer – A Challenge to Conventional Therapy

Nanotechnology-enhanced Immunotherapy for Metastatic Cancer

Nanobiotechnological approaches for breast cancer Management: Drug delivery systems and 3D In-Vitro models

Treating metastatic cancer with nanotechnology

Recent advances in nanoscale targeted therapy of HER2-positive breast cancer

Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages

Review of studies in field of the effects of nanotechnology on breast cancer

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

A review of nanomaterials from synthetic and natural molecules for prospective breast cancer nanotherapy

Bioengineering nanomaterials for tumor therapy and anti-metastasis

Recent Advances and Clinical Approach to Cancer Treatment with Nanotechnology Derived Biomolecule

Nano-drug delivery system: a promising approach against breast cancer

Cancer Bone Metastases and Nanotechnology-Based Treatment Strategies

Nanotechnology-based Intelligent Drug Design for Cancer Metastasis Treatment

Nanotechnology in cancer therapeutics, diagnosis, and management

Nanoscale strides: exploring innovative therapies for breast cancer treatment

Receptor-Targeted Surface-Engineered Nanomaterials for Breast Cancer Imaging and Theranostic Applications